Stay up to date with the latest developments in therapeutics by reading the world’s most respected source of authoritative drug information. For 50 years Drugs has been the definitive journal of drugs and therapeutics, promoting optimum pharmacotherapy by publishing reviews and original research authored by leading international clinicians and researchers to support clinical decision-making.   

Through a rigorous and comprehensive program of peer-reviewed evaluations, Drugs provides detailed and objective analysis covering the full spectrum of new and established drug therapies in all disease areas.

As a hybrid journal, Drugs does not charge authors to publish using the traditional subscription-based publishing route, but does offer the option to publish accepted articles open access if authors so wish or if their funders require. This is achieved via the Springer Open Choice™ initiative. More information about this optional route to open access and the associated article processing charge can be found by clicking on the ‘Learn about publishing Open Access with us’ link below.

Drugs offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.

Journal information

Editor
  • Dene Peters
Publishing model
Hybrid. Learn about publishing Open Access with us

Journal metrics

9.546 (2020)
Impact factor
7.641 (2020)
Five year impact factor

Latest articles

  1. Penpulimab: First Approval

    Authors

    • Sohita Dhillon
    • Content type: AdisInsight Report
    • Published: 23 November 2021
    • Pages: 2159 - 2166

Journal updates

View all updates

About this journal

Electronic ISSN
1179-1950
Print ISSN
0012-6667
Abstracted and indexed in
  1. BFI List
  2. BIOSIS
  3. CAB Abstracts
  4. CLOCKSS
  5. CNKI
  6. CNPIEC
  7. Chemical Abstracts Service (CAS)
  8. Current Contents/ Life Sciences
  9. Current Contents/Clinical Medicine
  10. Dimensions
  11. EBSCO Academic Search
  12. EBSCO Advanced Placement Source
  13. EBSCO Biomedical Reference Collection
  14. EBSCO CINAHL
  15. EBSCO Discovery Service
  16. EBSCO Nursing and Allied Health Collection
  17. EBSCO Rehabilitation & Sports Medicine Source
  18. EBSCO SPORTDiscus
  19. EBSCO STM Source
  20. EBSCO Science & Technology Collection
  21. EMBASE
  22. EMBiology
  23. EMCare
  24. Google Scholar
  25. Japanese Science and Technology Agency (JST)
  26. Journal Citation Reports/Science Edition
  27. Medline
  28. Naver
  29. OCLC WorldCat Discovery Service
  30. Pathway Studio
  31. Portico
  32. ProQuest-ExLibris Primo
  33. ProQuest-ExLibris Summon
  34. Reaxys
  35. SCImago
  36. SCOPUS
  37. Science Citation Index Expanded (SCIE)
  38. Semantic Scholar
  39. TD Net Discovery Service
  40. UGC-CARE List (India)
Copyright information

Rights and permissions

Springer policies

© Springer Nature Switzerland AG